124 related articles for article (PubMed ID: 1618556)
1. Role of neutral endopeptidase in the metabolism of endothelin.
Abassi ZA; Tate JE; Golomb E; Keiser HR
Hypertension; 1992 Jul; 20(1):89-95. PubMed ID: 1618556
[TBL] [Abstract][Full Text] [Related]
2. Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin.
Abassi Z; Golomb E; Keiser HR
Metabolism; 1992 Jul; 41(7):683-5. PubMed ID: 1535677
[TBL] [Abstract][Full Text] [Related]
3. Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rat.
Abassi ZA; Pieruzzi F; Nakhoul F; Keiser HR
Hypertension; 1996 May; 27(5):1140-8. PubMed ID: 8621208
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11.
Abassi ZA; Golomb E; Bridenbaugh R; Keiser HR
Br J Pharmacol; 1993 Aug; 109(4):1024-8. PubMed ID: 8401914
[TBL] [Abstract][Full Text] [Related]
5. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Jeng AY; Savage P; Beil ME; Bruseo CW; Hoyer D; Fink CA; Trapani AJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():98S-101S. PubMed ID: 12193064
[TBL] [Abstract][Full Text] [Related]
6. In vitro degradation of endothelin-1 by endopeptidase 24.11 (enkephalinase).
Fagny C; Michel A; Léonard I; Berkenboom G; Fontaine J; Deschodt-Lanckman M
Peptides; 1991; 12(4):773-8. PubMed ID: 1788141
[TBL] [Abstract][Full Text] [Related]
7. Phosphoramidon-sensitive conversion of big endothelin-1 and degradation of endothelin-1 in rat kidney.
Fujita K; Matsumura Y; Kita S; Hisaki K; Takaoka M; Morimoto S
Hypertension; 1994 Aug; 24(2):227-33. PubMed ID: 8039848
[TBL] [Abstract][Full Text] [Related]
8. Increased renal endothelin production in rats with reduced renal mass.
Benigni A; Perico N; Gaspari F; Zoja C; Bellizzi L; Gabanelli M; Remuzzi G
Am J Physiol; 1991 Mar; 260(3 Pt 2):F331-9. PubMed ID: 2000950
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis.
Sansoè G; Aragno M; Mastrocola R; Cutrin JC; Silvano S; Mengozzi G; Smedile A; Rosina F; Danni O; Rizzetto M
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1337-43. PubMed ID: 16449355
[TBL] [Abstract][Full Text] [Related]
10. Role of the neutral endopeptidase 24.11 in the conversion of big endothelins in guinea-pig lung parenchyma.
Lebel N; D'Orléans-Juste P; Fournier A; Sirois P
Br J Pharmacol; 1996 Jan; 117(1):184-8. PubMed ID: 8825361
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
Sharkovska Y; Kalk P; von Websky K; Relle K; Pfab T; Alter M; Fischer Y; Hocher B
Clin Lab; 2011; 57(7-8):507-15. PubMed ID: 21888014
[TBL] [Abstract][Full Text] [Related]
12. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Wegner M; Hirth-Dietrich C; Stasch JP
Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
[TBL] [Abstract][Full Text] [Related]
13. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
[TBL] [Abstract][Full Text] [Related]
14. Phosphoramidon inhibits the vasoconstrictor effects evoked by big endothelin-1 but not the elevation of plasma endothelin-1 in vivo.
Modin A; Pernow J; Lundberg JM
Life Sci; 1991; 49(22):1619-25. PubMed ID: 1943466
[TBL] [Abstract][Full Text] [Related]
15. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of ischemic acute renal failure by phosphoramidon in rats.
Vemulapalli S; Chiu PJ; Chintala M; Bernardino V
Pharmacology; 1993 Sep; 47(3):188-93. PubMed ID: 8415869
[TBL] [Abstract][Full Text] [Related]
17. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
[TBL] [Abstract][Full Text] [Related]
18. Hepatic effects of endothelin: metabolism of [125I]endothelin-1 by liver-derived cells.
Gandhi CR; Harvey SA; Olson MS
Arch Biochem Biophys; 1993 Aug; 305(1):38-46. PubMed ID: 8342954
[TBL] [Abstract][Full Text] [Related]
19. Degradation of endothelin-1 by extracts of rat lung, kidney, and liver.
Sirviö ML; Saijonmaa O; Metsärinne K; Fyhrquist F
Regul Pept; 1995 Feb; 55(3):219-25. PubMed ID: 7761621
[TBL] [Abstract][Full Text] [Related]
20. The fate of radioiodinated endothelin-1 and endothelin-3 in the rat.
Anggård E; Galton S; Rae G; Thomas R; McLoughlin L; de Nucci G; Vane JR
J Cardiovasc Pharmacol; 1989; 13 Suppl 5():S46-9; discussion S74. PubMed ID: 2473326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
